Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

44.49 -2.18 (-4.67%)
Streaming Delayed Price Updated: 1:10 PM EDT, Sep 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 509,369
Open 47.00
Bid (Size) 44.41 (1)
Ask (Size) 44.50 (1)
Prev. Close 46.67
Today's Range 43.98 - 47.59
52wk Range 20.63 - 71.98
Shares Outstanding 38,913,550
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
From Axsome Therapeutics, Inc.
Via Globe NewsWire
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets

Performance

YTD
+17.61%
+17.61%
1 Month
-30.75%
-30.75%
3 Month
+21.92%
+21.92%
6 Month
+11.17%
+11.17%
1 Year
+33.89%
+33.89%

More News

Read More
7 Top-Rated Biotech Stocks to Buy for Q4
Via InvestorPlace
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
Via InvestorPlace
Mizuho Bolsters Price Target By 55% On This Migraine Stock
Via Benzinga
Analyst Ratings for Axsome Therapeutics
Via Benzinga
Expert Ratings for Axsome Therapeutics
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Axsome Therapeutics Commences Late-Stage Migraine Study
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Boxed Warnings May Not Hinder This Depression Drug's Broad Market Penetration, Analyst Says
Via Benzinga
HC Wainwright Boosts Price Target On This Stock By 167%, Plus B of A Securities Predicts $40 For This Online Travel Stock
Via Benzinga
$1000 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
Via Investor's Business Daily
AXSOME THERAPEUTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
From Kahn Swick & Foti, LLC
Via Business Wire
AMC Entertainment Price Target Cut By This Analyst, Plus DA Davidson Predicts $318 For Estée Lauder
Via Benzinga
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
Via Benzinga
Stocks That Made New Highs On Friday, Aug. 19
Via Talk Markets
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
S&P 500 Down More Than 1%; Bed Bath & Beyond Shares Plummet
Via Benzinga
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Axsome Therapeutics Rockets After Winning FDA Approval For A New Depression Drug
Via Investor's Business Daily
Why Bed Bath & Beyond Is Trading Lower By Over 40%, Here Are 55 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.